New biomarker technique could provide early detection for cancer

Source: www.physorg.com
Author: press release provided by University of Connecticut

Modern genetic testing can predict your risk of contracting particular diseases based on predispositions discovered in your DNA. But what if similar biotechnology could tell you that you’ve got a disease before you notice any symptoms? What if it could even tell you, before any signs of a tumor, that you have cancer?

Jim Rusling, professor of chemistry at UConn and professor of cell biology at the UConn Health Center, ponders these questions on a daily basis. Since 2006, he and colleagues at the University and the National Institutes of Health (NIH) have been developing techniques to detect biomarker proteins – the physiological traits that indicate that a person has a specific disease – for prostate and oral cancer. Because these biomarkers are often present in the blood in a disease’s early stages, they can be used for early detection and prevention.

“DNA predicts which proteins can be made, but it can’t predict which proteins are actively expressed,” Rusling says. “It only assesses the risk of a disease. There’s a big push now to measure proteins as biomarkers.”

In a recent publication in the journal Analytical Chemistry, Rusling and his colleagues describe a system they developed to detect with record sensitivity the bloodstream levels of a protein associated with several types of oral cancer, including head and neck squamous cell carcinomas. The project was funded by a $1.5 million grant from the National Institute of Environmental Health Sciences at NIH.

The protein, called interleukin-6 or IL-6, is normally present in very low levels in the bloodstream – so low that previous biomarker sensors might not be able to detect it. This and other biomarkers are signaling molecules, which can instruct cells that have become cancerous to grow faster. Their levels can increase even before tumors begin to form, enabling early detection that might head off the formation of cancerous growths.

Alcohol’s hidden effects revealed in new National Health Service campaign

Source: www.medicalnewstoday.com
Author: staff

A new 6 million pound NHS campaign to reveal alcohol’s hidden effects warns people of the unseen damage caused by regularly drinking more than the advised limits and highlights drinkers’ affected organs while they sup their drink in the pub or at home.

The campaign was launched recently by Public Health Minister, Gillian Merron. It forms part of a government-wide strategy to tackle the harmful effects of alcohol and is backed by major health charities.

Merron said in a press statement that:

“Many of us enjoy a drink – drinking sensibly isn’t a problem.” But, she warned that:

“If you’re regularly drinking more than the NHS recommended limits, you’re more likely to get cancer, have a stroke or have a heart attack.”

The Department of Health developed the campaign with Cancer Research UK, the British Heart Foundation and the Stroke Association. Part of it entails showing a series of strong messages on TV, in the press and outdoor posters, showing how much harm drinking more than the NHS advised daily limit can do to your body.

In the TV campaign, one advert of three men drinking in a pub, shows one of them with a semi-transparent body, and as he sups his beer, different organs are highlighted to show which parts the narrator, who is explaining the risks of drinking alcohol, is talking about (for example, when high blood pressure is mentioned, the heart becomes more visible).

The NHS advises that women should drink no more than 2 to 3 units of alcohol a day (about 2 small glasses of wine) and men should drink no more than 3 to 4 a day(about two pints of lager).

In the UK, a unit of alcohol is 10 millilitres of ethanol (ethyl alcohol) and the strength of an alcoholic drink (the amount of ethyl alcohol it contains) is shown in percentage ABV (alcohol by volume). So every increase of 1% ABV adds another unit of alcohol to a litre: one litre of a drink of 1% ABV contains one unit of alcohol, one litre of 2% per cent ABV drink is 2 units, one litre of 3% ABV is 3 units, and so on.

However, most alcoholic drinks are stronger than 1 or 2% ABV and you don’t have to drink a litre to consume several units. For instance, one pint (just over half a litre) of beer at 4% ABV contains 2.3 units, and half a 0.75 litre bottle of wine at 13% ABV contains 4.9 units.

A recent YouGov poll of more than 2,000 adults showed that more than half (55 per cent) of drinkers in England mistakenly believe that alcohol only does harm if you regularly binge or get drunk.

The survey also revealed that 83 per cent of adults who drank more than the NHS advised daily limit don’t believe their drinking is putting their long- term health at risk.

This suggests that 8.3 of the 10 million adults in England who regularly drink above the recommended limit are probably unaware of how much damage their drinking is doing to their bodies, said the NHS.

Although the vast majority of those surveyed realised that alcohol consumption is linked to liver disease, few realised it is also linked to throat cancer, mouth cancer, breast cancer, stroke and heart disease.

This is in spite of evidence from research that shows, for example:

  • A man who regularly drinks more than two pints of lager a day is three times more likely to have a stroke or mouth cancer.
    A woman who regularly drinks more than two glasses of wine a day is 50 per cent more likely to get breast cancer, and twice as likely to have high blood pressure (which could lead to a heart attack).
  • According to figures from the Department of Health, over 9,000 people in the UK die from alcohol-related causes every year. Estimates from the World Health Organization (WHO) suggest that 20 per cent of alcohol-related deaths are from cancer, 15 per cent are from cardiovascular conditions like heart disease and stroke, and 13 per cent are from liver disease.

    Chief Medical Officer for England, Professor Sir Liam Donaldson, said that it was important for people to “realise the harm they, unknowingly, can cause to their health by regularly drinking more than the recommended daily limits.”

    “This campaign gives people the facts about the effect alcohol can have on their body and provides support for people who choose to drink less,” he added.

    Director of Communications for The Stroke Association, Joe Korner, said:

    “We are pleased to be involved in this campaign because it alerts people to the long term health risks of regular heavy drinking.”

    Korner said that stroke is the biggest cause of severe disability in adults and affects about 150,000 people every year in the UK, so it is vital that people understand that regularly drinking above the recommended daily limit means they are more likely to have high blood pressure, the single biggest risk factor for stroke.

    The British Heart Foundation’s Associate Medical Director, Dr Mike Knapton, urged that while there is some evidence that sensible drinking in moderation appears to offer some protection against heart disease, this should not be seen as a reason to take up drinking:

    “There are better ways to protect yourself from heart disease,” he said.

    “The evidence is clear, regularly drinking above the recommended daily limits harms the heart as well as causing a host of other harmful effects,” said Knapton.

    Sara Hiom, director of health information for Cancer Research UK said that decades of research has shown that alcohol can raise the risk of several cancers, including cancer of the bowel, breast, liver, mouth, foodpipe (oesophagus), voicebox (larynx) and throat.

    “Our bodies convert alcohol into a toxic chemical called acetaldehyde which can lead to cancer by damaging DNA and stopping our cells from repairing this damage,” explained Hiom, adding that another side effect of alcohol consumption is raised levels of estrogen which increases the risk of breast cancer.

    “The simple message is that the more you drink the greater your cancer risk but the more you cut down the more you reduce that risk,” said Hiom.

    March, 2010|Oral Cancer News|

    New test genetically fingerprints tumors

    Source: online.wsj.com
    Author: Ron Winslow

    In a fresh advance for the burgeoning field of personalized medicine, researchers have developed a blood test based on the DNA of tumors that could help tailor treatment for individual cancer patients.

    The report, announced Thursday, represents one of the most tangible examples yet of how the ability to sequence a person’s entire genetic code could have a direct impact on patient care. There have been a flurry of reports on new sequencing technology that is yielding enormous amounts of information about genetics and disease, but that has yet to deliver much in the way of new treatment strategies.

    “For cancer patients there hasn’t been much utility so far. This may prove to be one of the first useful approaches,” said Victor Velculescu, co-director of the cancer biology program at Johns Hopkins University’s Kimmel Cancer Center and senior author of the new study.

    Much research involving whole-genome sequencing is aimed at finding differences in the individual letters that make up the genetic code. The belief is that those small alterations will point to molecular pathways that regulate disease, which would be potential targets for drug therapies.

    The Hopkins researchers, writing in the journal Science Translational Medicine, took a different approach. They scanned the DNA of tumors taken from six patients with breast or colon cancer, looking not for tiny DNA changes, but what they call rearrangements in large sections of the genome of tumor cells. The DNA of tumors varies genetically from that of normal tissue, and the rearrangements are essentially a fingerprint of the cancer.

    The findings suggest that by testing blood for this fingerprint, doctors will be able to learn whether a patient treated for cancer is free of disease or needs additional or more aggressive care.

    “It’s a very clever use of the [sequencing] technology,” said Jeffery Schloss, program director for genome technology at the National Human Genome Research Institute, a division of the National Institutes of Health.

    Dr. Schloss, who wasn’t involved with the Hopkins study, likened the approach to drawing a map. Sequencing the letters of the genetic code would be akin to plotting every house in a large neighborhood. The Hopkins team was looking only for neighborhoods—in particular, neighborhoods out of place compared with where they would be in normal tissue.

    The uniqueness of such “neighborhood” rearrangements is what makes the DNA a good biomarker for the status of tumors, Dr. Velculescu said. A blood test can detect evidence of even minuscule levels of such alterations. That can indicate, for instance, whether a tumor may be progressing after initially responding to treatment or whether any residual disease is present after surgery to remove a tumor. That could help a doctor and patient decide what other treatment options to pursue.

    In the study, researchers tracked for two years one patient whose disease initially responded to treatment and then recurred. Levels of the DNA marker in the patient’s blood accurately reflected the course of the disease, researchers said. The test wouldn’t help predict which drugs a patient is likely to respond to—that likely would require a more detailed DNA scan, researchers said.

    This advance comes as the cost of sequencing a patient’s entire genome has fallen sharply—to less than $10,000 now from about $1 million three years ago, according to companies that make sequencing machines. Experts predict that the cost will soon get to about $1,000, potentially making it affordable for medical centers to routinely run the genome of patients with cancer and other diseases.

    Currently, cancer doctors often use CT scans to check on the status of a tumor—at a cost of about $1,500, the Hopkins researchers said. They estimated the current cost of the DNA test at about $5,000 but suggest the cost will soon be comparable to a CT scan.

    Hopkins has filed patents for the technology. Dr. Velculescu and two other co-authors of the paper are entitled to a share of royalties on sales of any products related to the research if it is commercialized. Further research is necessary to validate the approach with more patients and more cancer types, but researchers said such a test could be ready to use within two years and widely available “within several years.”

    February, 2010|Oral Cancer News|

    Human papillomavirus, p16 and p53 expression associated with survival of head and neck cancer

    Source: 7thspace.com
    Author: staff

    P16 and p53 protein expression, and high-risk human papillomavirus (HPV-HR) types have been associated with survival in head and neck cancer (HNC). Evidence suggests that multiple molecular pathways need to be targeted to improve the poor prognosis of HNC.

    This study examined the individual and joint effects of tumor markers for differences in predicting HNC survival. P16 and p53 expression were detected from formalin-fixed, paraffin-embedded tissues by immunohistochemical staining. HPV DNA was detected by PCR and DNA sequencing in 237 histologically confirmed HNC patients.

    Overexpression of p16 (p16+) and p53 (p53+) occurred in 38% and 48% of HNC tumors, respectively. HPV-HR was detected in 28% of tumors. Worse prognosis was found in tumors that were p53+ (disease-specific mortality: adjusted hazard ratios, HR=1.9, 95% CI: 1.04-3.4) or HPV (overall survival: adj. HR=2.1, 1.1-4.3) but no association in survival was found by p16 status.

    Compared to the molecular marker group with the best prognosis (p16+/p53/HPV-HR: referent), the p16/p53+/HPV group had the lowest overall survival (84% vs. 60%, p<0.01; HR=4.1, 1.7-9.9) and disease-specific survival (86% vs.

    66%, p<0.01; HR=4.0, 1.5-10.7). Compared to the referent, the HRs of the other six joint biomarker groups ranged from 1.6-3.4 for overall mortality and 0.9-3.9 for disease-specific mortality.

    The p16/p53/HPV joint groups showed greater distinction in clinical outcomes compared to results based on the individual biomarkers alone. This finding suggests that assessing multiple molecular markers in HNC patients will better predict the diverse outcomes and potentially the type of treatment targeted to those markers.

    Author: Elaine SmithLinda RubensteinHenry HoffmanThomas HaugenLubomir Turek
    Credits/Source: Infectious Agents and Cancer 2010, 5:4

    February, 2010|Oral Cancer News|

    New DNA therapy for advanced mouth cancer

    Source: www.dentistry.co.uk
    Author: staff

    A research team has been awarded a patent after developing a new DNA therapy for head and neck cancer sufferers. Researchers from the University of Pittsburgh School of Medicine in the US, aims to develop a safe and effective alternative to standard chemotherapy treatments which cause debilitating side-effects.

    Based on a form of genetic therapy called ‘antisense’, the new DNA therapy injections target the epidermal growth factor receptor (EGFR), blocking the growth of a protein which is found on the surface of many types of cancer cells.

    During the initial Cancer Institute study, led by Dr Jennifer Grandis, the injections were well-tolerated, and the tumours which were being targeted by the treatment disappeared or shrank considerably in more than a quarter of the patients.

    The British Dental Health Foundation has welcomed the latest development in treating this deadly disease. Chief executive Dr Nigel Carter said: ‘These new findings show that this new DNA therapy can have the potential as both a safe and effective advanced cancer treatment.

    One of the major problems with mouth cancer is that it often presents in late stages, significantly reducing survival – so a late stage treatment is particularly welcome.

    ‘Head and neck cancers have a strong association with environmental and lifestyle risk factors including smoking tobacco, alcohol consumption and the sexually transmitted human papilloma virus (HPV).

    ‘Research has recently suggested that the HPV virus, transmitted via oral sex, could soon become the most common cause of mouth cancer.’ Cancers caused by viral infections can also be prevented by making positive lifestyle changes to reduce these risks.

    World Cancer Day was marked around the globe yesterday (Thursday 4 February) in an effort to highlight the link between infections and cancer.

    Dr Carter said: ‘Thirty per cent of mouth cancer cases have been linked to a poor diet. Eating a balanced diet with plenty of fruit and vegetables, quitting smoking and cutting down on alcohol consumption lowers the risk of mouth cancer.’

    The British Dental Health Foundation’s Mouth Cancer Action Month campaign, which runs each November in the UK with the message of ‘If In Doubt, Get Checked Out’, stresses the importance of following this advice by undertaking regular dental visits and self-examination.

    February, 2010|Oral Cancer News|

    HPV-associated base of tongue squamous cell carcinoma incidence increasing in Sweden

    Source: www.hemonctoday.com
    Author: staff

    The incidence for base of tongue squamous cell carcinoma increased significantly in Sweden between 1998 and 2007, and by 2007, more than 80% of these cases were HPV-positive.

    Various studies during the past 20 years have indicated that HPV is a risk factor for oropharyngeal cancer. However, few studies have assessed the specific sub-sites of the oropharynx.

    In this study, researchers assessed the increased incidence of base of tongue cancer and the association of HPV in 109 patients diagnosed with base of tongue cancer between 1998 and 2007 in Stockholm, Sweden.

    The researchers obtained diagnostic pretreatment paraffin-embedded tumor biopsies from 95 patients. DNA samples were obtained from 30-mcm paraffin-embedded base of tongue biopsy slices. Age at diagnosis ranged from 41 to 85 years.

    From 1970 to 2007, the age-standardized incidence of base of tongue squamous cell carcinoma increased from 0.15 per 100,000 person-years between 1970 and 1974 to 0.47 per 100,000 person-years between 2005 and 2007.

    HPV DNA was found in 75% of base of tongue cancer cases during this time. Of the HPV-positive tumors, 86% were HPV-16–positive and seven were HPV-33–positive.

    During the study period, the incidence of HPV-positive base of tongue cancers persistently increased (see chart). A significant increase was found in the proportion of HPV-positive cancer between 1998 and 2001 compared with 2004 and 2007 (58% vs. 84%; P<.05).

    When compared with patients with HPV-negative tumors, patients with HPV-positive tumors were likely to be stage IV (P<.02) and had less advanced T-stage (P<.05 for T2; P<.01 for T3); however, these patients had more advanced N-stage (P<.01 for N0; P<.01 for N2a-c).

    Source: Attner P. Int J Cancer. 2010;doi:10.1002/ijc.24994.

    February, 2010|Oral Cancer News|

    1,000: the magic number in genomic research

    Source: www.minnpost.com
    Aurhor: Sharon Schmickle

    The number 1,000 is emerging as a standard benchmark on the frontiers of genomic research.

    In the 1000 Genomes Project — launched two years ago — American, British, Chinese and German scientists are sequencing the genomes of some 1,000 individuals from around the world in order to aid medical research as it relates to human genetic variation.

    Then there’s the goal of the $1,000 genome. Reduce the cost of accurately spelling an individual’s DNA to that level and we could see practical results from decades of genomic discovery — even at the clinical level. A research team from Complete Genomics Inc. in Mountain View, California, reported progress in that regard this week in the journal Science.

    Now comes a new report from the “1,000 tumor” project at the University of Chicago’s Institute for Genomics and Systems Biology.

    The Chicago scientists are working toward the goal of collecting and analyzing the genetic sequences and variations of every gene expressed by 1,000 tumors. One year into the three-year project, they have completed data for genes expressed by 100 tumors — primarily breast cancer, head and neck cancer, and leukemia. In the process, they have streamlined techniques for analyzing the remaining 900 tumors.

    Meanwhile, by correlating genetic data with patient outcomes, the Chicago team has begun to identify genetic patterns within tumors that may help them predict how a cancer will behave. Eventually, the research should help identify which patients would benefit from which treatments.

    We must have at least 1,000 genome projects around the world at this point in the research. Has anyone bothered to count?

    The Mayo Clinic reported in November that its cancer research team in Arizona has completed its first whole human genome sequencing on a patient with multiple myeloma, a cancer of the bone marrow. Among other information, they captured an entire snapshot of the patient’s cancer cells through various stages of the disease.

    Mayo teams in Rochester, Minn., are working on other genomic studies as are scientists at the University of Minnesota.

    This will be a great field to watch in this new decade.

    January, 2010|Oral Cancer News|

    Liverpool scientists working on vaccine for mouth cancer

    Source: www.liverpoolecho.co.uk
    Author: Liza Williams

    ONE central project the scientists and doctors are working on is a vaccine for mouth cancer. Liverpool researchers have found some cases are caused by the HPV virus – the same bug which causes cervical cancer. They have discovered that two-thirds of tonsil cancer tumour samples showed evidence of the HPV-16 gene.

    The work is particularly important because the researchers are also seeing the rates of tonsil cancer doubling in non-smokers and non-drinkers – two of the main causes of the disease.

    They have found a DNA test helps to predict whether a patient has HPV. This could be used to decide which treatment is best for the patient, because both chemo and radiotherapy are more successful in patients with the virus.

    They are now developing a clinical trial for a HPV vaccine for head and neck cancer, like the jab given to teenage girls to prevent cervical cancer.

    January, 2010|Oral Cancer News|

    Scientists decode entire genetic code of cancer

    Source: www.popsci.com
    Author: Jeremy Hsu

    And cigarette smokers get a free mutation in every pack

    In a major step toward understanding cancer, one of the biggest problems bedeviling modern medicine, scientists have now cracked the genetic code for two of the most common cancers. This marks just the beginning of an international effort to catalog all the genes that go wrong among the many types of human cancer, the BBC reports.

    Cracking the Cancer Code A cluster of breast cancer cells, with blue ones marking actively growing cells and yellow marking dying cells. Could scientists crack their code next?
    Cracking the Cancer Code A cluster of breast cancer cells, with blue ones marking actively growing cells and yellow marking dying cells. Could scientists crack their code next?

    Too much time spent under the sun apparently leads to most of the 30,000 mutations contained within the DNA code for melanoma, or skin cancer. Outside experts told the BBC that no previous study has managed to link specific mutations to their causes.

    Wellcome Trust scientists also found more than 23,000 errors in the lung cancer DNA code, with most caused by cigarette smoke exposure. A typical smoker might get one new mutation, possibly harmless but also possibly a cancer trigger, for every 15 cigarettes that they smoke.

    The new cancer maps could lead to better blood tests for diagnosing the respective cancers, as well as better targeted drugs. Blood tests might even reveal the DNA patterns that suggest cancer lies on the horizon.

    The International Cancer Genome Consortium still expects to spend hundreds of thousands of dollars in cracking the code of the many human cancers. The U.S. has the job of studying cancers of the brain, ovary and pancreas, while the UK examines breast cancer. China is tasked with decoding stomach cancer, Japan is focused on liver cancer, and India has taken a crack at mouth cancer.

    This painstaking research can only help futuristic treatment efforts, such as nanoparticle-targeted lasers and do-it-all nanoparticles that can track, tag and kill cancer cells. But those cancer-resistant mole rats should still count their lucky stars.

    December, 2009|Oral Cancer News|

    Microarray technologies in the diagnosis and treatment of head and neck cancer

    Source: emedicine.medscape.com
    Authors: Perminder S Parmar, MD et al.

    Since the draft sequence of the human genome was published in 2001 (Lander, 2001), the Cancer Genome Anatomy Project index of tumor genes has classified more than 40,000 genes directly or indirectly involved in one or more cancers (Strausberg, 2001; Strausberg, 2000). Conventional techniques of gene investigation in cancer rely on the identification of single genetic alterations associated with disease. This has proven to be both time consuming and cost ineffective. The introduction of complementary DNA (cDNA) microarray technology in 1995 (Schena, 1995) has helped to facilitate the identification and classification of DNA sequence information and the assignment of functions to these new genes by allowing investigators to analyze expression of thousands of genes simultaneously in a single experiment.

    Microarrays are a significant advance because they contain a very large number of genes and because of their small size. Therefore, microarrays are useful when one wants to survey a large number of genes quickly or when the study sample is small. Microarrays may be used to assay gene expression within a single sample or to compare gene expression in 2 different cell types or tissue samples, such as in healthy and diseased tissue. Because a microarray can be used to examine the expression of hundreds or thousands of genes at once, it promises to revolutionize the way gene expression is examined.

    DNA microarrays are small solid supports onto which the sequences from thousands of different genes are attached at fixed locations. The supports themselves are usually glass microscope slides but can also be silicon chips or nylon membranes. The DNA is printed, spotted, or actually synthesized directly onto the support.

    Messenger RNA (mRNA) from the sample of interest can serve as a template for producing complementary DNA (cDNA) in the presence of a reverse transcriptase enzyme. This cDNA can then be fluorescently labeled and hybridized to the target gene sequences on the microarray. A confocal scanner then reads the fluorescent intensity of each hybridized sequence in the array. The scanner that records the intensity value is linked to digital image analysis software, which produces a color-coded image of the array, and a quantitative value is recorded for each target gene. The intensity of fluorescence is analyzed and correlates with expression of the gene.

    The data produced from a microarray experiment typically constitute a long list of measurements of spot intensities and intensity ratios, generated either by a pair-wise comparison of 2 samples or by a comparison of several samples with a common control. The challenge is to sort through this data to find meaningful results. Because of the complexity of the data sets generated by microarray experiments, the use of data-analysis software is essential. Several commercial and public data-analysis tools have been developed for this purpose.

    Current Applications In Head And Neck Oncology
    In recent years, the use of microarray technology has been of great interest in head and neck squamous cell carcinoma (HNSCCa). Microarrays may eventually help in the understanding of the disease and ultimately lead to improvements in diagnosis, treatment, and outcome (Warner, 2004). Furthermore, the quantitative and qualitative aspect of microarrays may eventually be exploited to screen for molecular markers of head and neck cancer (Sok, 2003). Numerous expression studies of HNSCCa have been performed (Sok, 2003; Belbin, 2002; Villaret, 2000; Leethanakul, 2000; Squire, 2002).

    Belbin et al used complementary DNA (cDNA) microarrays that contained 9216 clones to measure global patterns of gene expression in HNSCCa. Through the use of statistical analysis, they identified 375 differentially expressed genes, which divided 17 patients with head and neck tumors into 2 clinically distinct subgroups based on gene-expression patterns. The results of their analysis demonstrated that gene-expression profiling can be used as a predictor of outcome and highlighted pathways, meriting exploration for possible links to outcome in HNSCC.

    Using cDNA subtractive methodology in conjunction with microarray technology to screen for HNSCCa-specific genes, Villaret et al were able to identify 9 known genes that were significantly overexpressed in HNSCCa compared with healthy tissue specimens. In addition, they found 4 previously unidentified genes that were overexpressed in a subset of tumors.

    Using a cDNA array of 588 known human cancer-related genes and 9 housekeeping genes, Leethanakul et al demonstrated a consistent decrease in the expression of differentiation markers, such as cytokeratins, and an increase in the expression of numerous signal-transducing and cell cycle regulatory molecules, as well as growth and angiogenic factors and tissue-degrading proteases. The authors also found that most HNSCCas overexpress members of the Wnt and Notch growth and differentiation regulatory system, suggesting that the Wnt and Notch pathways may contribute to squamous cell carcinogenesis.

    In their study, Squire et al, using spectral karyotyping (SKY), comparative genomic hybridization (CGH), and microarrays, identified consensus regions of chromosomal imbalance and structural rearrangement in HNSCCa. The authors were able to demonstrate recurrent chromosomal alterations using CGH and SKY and to correlate them to expression array analysis.

    In their study, Sok et al, using hierarchical clustering analysis, revealed that the gene-expression profiles obtained from a panel of 12,000 genes could distinguish tumor from nonmalignant tissues. Gene expression changes were reproducibly observed in 227 genes, representing previously identified factors associated with neoplasia. Furthermore, significant expression of the collagen type XI alpha-1 gene and a novel gene were reproducibly observed in all 9 tumors, whereas these genes were virtually undetectable in their corresponding, adjacent nonmalignant tissues.

    Despite strides in prevention and advances in treatment, cancer of the head and neck remains a disease of considerable morbidity and mortality. The use of complementary DNA (cDNA) microarray technology to explore gene expression on a global level is rapidly evolving. Although still in its infancy, cDNA microarray technology may prove helpful in the diagnosis, prognosis, and management of head and neck cancer.

    Authors and affiliations:
    James M Pearson, MD, Staff Physician, Department of Otolaryngology – Head and Neck Surgery, New York Eye and Ear Infirmary; Stimson P Schantz, MD, Head, Department of Otolaryngology, Division of Head and Neck Surgery, New York Eye and Ear Infirmary

    November, 2009|Oral Cancer News|